UBS AM
BNTX icon

UBS AM’s BioNTech BNTX Stock Holding History

UBS AM’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.2M Sell
744,200
-39,795
-5% -$3.75M 0.01% 577
2026
Q1 		$69.7M Buy
783,995
+533,664
+213% +$54.8M 0.01% 571
2025
Q4 		$23.8M Buy
+250,331
New +$25.2M 0.01% 798
2025
Q3 		– Sell
-256,874
Closed -$27.3M – 2327
2025
Q2 		$27.3M Buy
256,874
+38,452
+18% +$3.88M 0.01% 923
2025
Q1 		$19.9M Sell
218,422
-2,658
-1% -$298K 0.01% 969
2024
Q4 		$25.2M Buy
221,080
+36,746
+20% +$4.19M 0.01% 863
2024
Q3 		$21.9M Sell
184,334
-47,213
-20% -$4.34M 0.01% 908
2024
Q2 		$18.6M Buy
231,547
+17,558
+8% +$1.6M 0.01% 889
2024
Q1 		$19.7M Sell
213,989
-781,264
-78% -$74.9M 0.01% 796
2023
Q4 		$105M Buy
995,253
+137,115
+16% +$13.8M 0.04% 421
2023
Q3 		$93.2M Buy
858,138
+397,315
+86% +$43.9M 0.04% 417
2023
Q2 		$57.4M Hold
460,823
– – 0.03% 523
2023
Q1 		$57.4M Sell
460,823
-19,478
-4% -$2.67M 0.03% 523
2022
Q4 		$72.2M Buy
480,301
+140,865
+41% +$21.7M 0.04% 461
2022
Q3 		$45.8M Buy
339,436
+134,663
+66% +$20.6M 0.03% 574
2022
Q2 		$30.5M Buy
204,773
+24,700
+14% +$3.77M 0.02% 648
2022
Q1 		$30.7M Buy
180,073
+28,446
+19% +$4.78M 0.01% 730
2021
Q4 		$39.1M Buy
151,627
+58,400
+63% +$16M 0.02% 716
2021
Q3 		$25.5M Sell
93,227
-33,271
-26% -$10.6M 0.01% 810
2021
Q2 		$28.3M Sell
126,498
-201,340
-61% -$38M 0.01% 795
2021
Q1 		$35.8M Buy
327,838
+46,556
+17% +$4.94M 0.02% 705
2020
Q4 		$22.9M Buy
281,282
+141,090
+101% +$13.9M 0.01% 818
2020
Q3 		$9.71M Sell
140,192
-62,014
-31% -$4.45M 0.01% 950
2020
Q2 		$13.5M Buy
+202,206
New +$10.1M 0.01% 841

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

UBS AM's BNTX Position: Q2 2026 in Review

UBS AM reduced its BioNTech (BNTX) stake by 5.1% in Q2 2026, selling an estimated $3.75M and leaving 744,200 shares worth $69.2M. The position accounts for 0.01% of the portfolio, ranked #577.

UBS AM first reported a position in BNTX in Q2 2020 and has held it in 24 quarters since. The position peaked at $105M in Q4 2023. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • UBS AM held 744,200 shares of BioNTech worth $69.2M as of Q2 2026.
  • UBS AM sold 39,795 BioNTech shares in Q2 2026, an estimated $3.75M.
  • BioNTech made up 0.01% of UBS AM's portfolio in Q2 2026, its #577 holding.
  • UBS AM first reported a position in BioNTech in Q2 2020 and has held it in 24 quarters since.
  • UBS AM's BioNTech position peaked at $105M in Q4 2023.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.